Moran Wealth Management LLC Has $8.95 Million Holdings in DaVita Inc. (NYSE:DVA)

Moran Wealth Management LLC lifted its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 3,487.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,566 shares of the company's stock after purchasing an additional 53,045 shares during the period. Moran Wealth Management LLC owned about 0.07% of DaVita worth $8,945,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Harvard Management Co. Inc. acquired a new position in DaVita during the second quarter worth $55,115,000. KBC Group NV raised its position in shares of DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company's stock worth $51,395,000 after purchasing an additional 67,250 shares during the last quarter. Lazard Asset Management LLC lifted its stake in DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company's stock valued at $35,460,000 after buying an additional 153,008 shares in the last quarter. Andra AP fonden increased its position in DaVita by 9.0% during the second quarter. Andra AP fonden now owns 192,300 shares of the company's stock worth $26,647,000 after buying an additional 15,800 shares in the last quarter. Finally, abrdn plc raised its holdings in shares of DaVita by 1.2% in the third quarter. abrdn plc now owns 189,065 shares of the company's stock worth $30,719,000 after acquiring an additional 2,180 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 50,000 shares of the firm's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the firm's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now directly owns 111,481 shares of the company's stock, valued at approximately $17,286,243.86. This trade represents a 36.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 156,086 shares of company stock worth $24,807,161. Insiders own 2.00% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Truist Financial raised their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. UBS Group boosted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, August 8th. Bank of America boosted their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research report on Wednesday, August 7th. Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Finally, TD Cowen boosted their target price on shares of DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $161.80.

DaVita Trading Up 1.3 %

NYSE DVA traded up $2.14 on Thursday, hitting $163.54. 161,774 shares of the company were exchanged, compared to its average volume of 819,674. The company's 50 day moving average price is $158.14 and its 200-day moving average price is $147.97. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The firm has a market capitalization of $13.41 billion, a P/E ratio of 17.41, a price-to-earnings-growth ratio of 0.89 and a beta of 0.89. DaVita Inc. has a twelve month low of $97.31 and a twelve month high of $168.50.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the prior year, the company earned $2.85 EPS. DaVita's revenue for the quarter was up 4.6% on a year-over-year basis. Analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.